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Abstract
Background: Cysteine sulfenic acid (Cys-SOH) plays important roles in the redox regulation of numerous proteins.
As a relatively unstable posttranslational protein modification it is difficult to quantify the degree to which any
particular protein is modified by Cys-SOH within a complex biological environment. The goal of these studies was
to move a step beyond detection and into the relative quantification of Cys-SOH within specific proteins found in
a complex biological setting–namely, human plasma.
Results: This report describes the possibilities and limitations of performing such analyses based on the use of
thionitrobenzoic acid and dimedone-based probes which are commonly employed to trap Cys-SOH. Results
obtained by electrospray ionization-based mass spectrometric immunoassay reveal the optimal type of probe for
such analyses as well as the reproducible relative quantification of Cys-SOH within albumin and transthyretin
extracted from human plasma–the latter as a protein previously unknown to be modified by Cys-SOH.
Conclusions: The relative quantification of Cys-SOH within specific proteins in a complex biological setting can be
accomplished, but several analytical precautions related to trapping, detecting, and quantifying Cys-SOH must be
taken into account prior to pursuing its study in such matrices.
Background
A rapidly expanding body of evidence demonstrates that
cysteine sulfenic acid (Cys-SOH) formation within pro-
tein molecules can serve as a means of regulating pro-
tein activity. Under variant biochemical circumstances it
may serve to mediate redox signaling [1-5], fundamen-
tally alter protein activity [1,2,4-13], or absorb and
deflect oxidative insults [1,10,11,14-20]. Much of this
evidence has only recently come to light because the
unstable, transient nature of Cys-SOH has prevented its
thorough study in decades past: As a protein modifica-
tion it is generally unstable unless enveloped within a
stabilizing protein microenvironment.
The ability to quantify the extent to which individual
proteins are modified by Cys-SOH in complex biological
matrices is an important step in understanding the full
range of biological processes in which the posttransla-
tional modification plays a role. Naturally, complex
biological samples represent the ultimate context for
such relative-percent-abundance (RPA) determinations
of protein Cys-SOH. But a combined lack of spectral
absorption properties and chemical instability have his-
torically left few options available with regard to analyz-
ing protein Cys-SOH in even the simplest matrix.
Covalent trapping with a sulfenic acid-specific probe
that changes an intrinsic property (e.g., mass or optical
absorbance characteristics) of labeled protein molecules
is, currently, the only viable path of routine detection.
To date, the most commonly used chemical traps
of Cys-SOH are molecules with dimedone or
sulfhydryl functional groups [3,6,21-24]. These have
been employed successfully and are quite useful in the
analysis of isolated proteins; the former have even been
applied to detecting the presence of protein Cys-SOH in
biological samples [5,25-28]. But the molecular com-
plexity of biological samples imparts a layer of analytical
difficulty that has yet to be overcome with regard to
determining the precise degree to which specifically tar-
geted proteins are modified by Cys-SOH in their native
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environments. Thus, beyond simple (positive or nega-
tive) detection of Cys-SOH within specific proteins or
the relative quantification of Cys-SOH in many proteins
together in bulk, little has been developed in the way of
technologies to quantify the precise degree to which
particular proteins within complex biological samples
are modified by Cys-SOH.
Herein we report on the application of mass spectro-
metric immunoassay (MSIA) [29-34] to the detection
and relative quantification of Cys-SOH as it modifies
specifically targeted proteins in human plasma. MSIA is
high throughput affinity chromatography, followed by
the analysis of intact proteins by mass spectrometry,
using relative mass spectral peak intensities correspond-
ing to modified and unmodified protein forms as repre-
sentative of their relative abundances [35]. This is a well
established analytical procedure [29,32,33,36-42] and is
analogous to an ultra-high resolution, semiquantitative
western blot. In addition to the now well known exam-
ple of albumin [14,15,24,43,44] we report on the RPA of
previously undocumented Cys-SOH formation in trans-
thyretin (TTR) as it occurs within the biological matrix
of human plasma. Taken altogether, however, our
results also compel the description of several analytical
precautions related to trapping, detecting, and quantify-
ing Cys-SOH in complex biological samples.
Results and Discussion
Detection and Relative Quantification of Cys-SOH For-
mation within Specific Plasma Proteins: The strategy
taken was to trap Cys-SOH, then extract and analyze all
molecular forms of targeted proteins using MSIA. Albu-
min and TTR serve as ideal model proteins by which to
assess this strategy because each possesses a single free
cysteine residue–meaning that only one mole of Cys-
SOH can form per mole of protein.
Albumin and TTR were immunoaffinity-extracted
from human plasma that was treated with hydrogen per-
oxide and the dimedone-based Cys-SOH trapping
reagent 5-[2-(3-chlorophenoxy)phenyl]-4-(1H-1,2,4-tria-
zol-1-yl)-1,3-cyclohexanedione (CPPCHD; Figure 1).
Dimedone itself and other dimedone-based probes such
as DCP-Bio1 [23] produce qualitatively analogous
results. The high mass of dimedone-based probes such
as CPPCHD and DCP-Bio1 provides a significant mass
shift to the protein such that tagged protein molecules
lie out of the mass range of commonly observed post-
translationally modified protein variants. For example,
S-cysteinylation (Δm +119 Da) and S-Cysteinylglycinyla-
tion (Δm +176 Da) are frequently observed as posttran-
slationally modified forms of free cysteine-containing
proteins (Figure 1, [32,37]). The RPA of each posttran-
slationally modified form of the proteins analyzed in
Figure 1 are listed in Table 1.
Because it can readily be analyzed intact by ESI-MS
after a simple ~1000-fold dilution of plasma, albumin
serves as a convenient model protein by which to assess
the accuracy and precision of these techniques for rela-
tive quantification of Cys-SOH-modified protein. By
comparing the RPA of Cys-SOH modified albumin
detected following plasma preparation by dilution vs.
immunoaffinity extraction, it can be determined whether
or not antibodies bind dimedone-tagged forms of the
proteins with different affinity than that with which they
bind naturally occurring form(s). (By the term “dime-
done-tagged” we refer to molecules that bear a 1,3-
cyclohexanedione (dimedone-like) functional group.)
To begin to assess the accuracy and precision of the
technique for determining the RPA of Cys-SOH modi-
fied proteins, a series of experiments were run in which
human plasma was exposed to increasing concentrations
of hydrogen peroxide to generate abundant quantities of
Cys-SOH. Plots of the RPA of dimedone-tagged target
protein vs. hydrogen peroxide concentration (Figure 2)
reveal two potential problems. First, by comparing the
RPA (y-axis) of tagged albumin when analyzed by dilu-
tion vs. MSIA (for both dimedone-based probes; Figure
2, Panels A and B), a quantitative discrepancy is readily
apparent in which the MSIA-based technique reports a
lower RPA of covalently tagged albumin than the dilu-
tion technique. The most likely explanation for this phe-
nomenon is that there is a diminished binding affinity of
the anti-albumin antibodies for tagged forms of the
protein. Second, by comparing the RPA of Cys-SOH
modified albumin reported by the two different dime-
done-based probes across a series of hydrogen peroxide
concentrations (Figure 2, Panel A vs. B, solid squares), a
substantial quantitative discrepancy is readily apparent:
DCP-Bio1 was present in solution at a higher concentra-
tion than CPPCHD but results in lower apparent values
for RPA of Cys-SOH. This is most likely due to differ-
ences in reaction rates between the two probes for the
Cys-SOH site. This brings up the question of which, if
either probe reports a truly accurate (surrogate) quanti-
tative value for the RPA of Cys-SOH originally present
in the plasma.
The final calculated concentrations of CPPCHD and
DCP-Bio1 in solution were 9 mM and 17 mM, respec-
tively. However it is possible that these final concentra-
tions may not have actually been reached due to
solubility issues: CPPCHD has a calculated (ALOGpS
[45]) aqueous solubility of about 25 μM and DCP-Bio1
of about 120 μM. However, the existence of 5-10%
DMSO in solution coupled with evidence from others
that DCP-Bio1 shows increased rates of alkylation of
pure protein with increasing concentrations of DCP-
Bio1 up to about 1 mM [23,46], leads to the final con-
clusion that both probes were saturated in solution and
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that the concentration of DCP-Bio1 was higher than
that of CPPCHD.
But even at saturating concentrations, the rates of
reaction of dimedone-based probes with Cys-SOH are
slow enough that, in a complex biological fluid like
human plasma, resulting reports of Cys-SOH RPA stand
to be in error because of the presence of endogenous
free small molecule thiols such as cysteine, homocys-
teine, and glutathione which react much faster with pro-
tein Cys-SOH than dimedone [24]. The concentration of
free cysteine in human plasma is typically in the 1-10
μM range [47], if not more [47-49]. Experimentally, evi-
dence for the competitive reaction of endogenous free
cysteine with protein Cys-SOH can readily be seen vis-
à-vis an increase in the intensity of the peaks represent-
ing S-cysteinylated albumin and TTR in samples to
which hydrogen peroxide was added to generate Cys-
SOH (Figure 1 and Table 1). This is a fundamental lim-
itation of dimedone-based probes of protein Cys-SOH.
By nature no surrogate trapping technique can guar-
antee a quantitatively perfect representation of a trapped
molecular species–particularly when the species to be
trapped are molecularly unstable and there is endogen-
ous competition for reaction with them. This suggests
that, other factors held equal, the trapping reagent with
the fastest reaction rate toward the unstable target
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Figure 1 Mass spectra of A) albumin and B) TTR extracted from human plasma that was treated with/without hydrogen peroxide and
with/without the dimedone-based Cys-SOH trapping reagent CPPCHD. For albumin (A), deconvoluted “MH+“ peaks are assigned as follows:
66438 = Native/unmodified (Calc. 66439), 66557 = S-Cysteinylated (Calc. 66558), 66600 = Glycated native form (Calc. 66601), 66614 = S-CysGly
(Calc. 66615), 66719 = Glycated S-Cysteinylated form (Calc. 66720), 66818 = CPPCHD-modified native form (Calc. 66819). For TTR (B), 13761 =
Native/unmodified (Calc. 13762), 13793 = Cys-sulfinic acid (SO2H) due to over oxidation (Calc. 13794), 13880 = S-Cysteinylated (Calc. 13881),
13937 = S-CysGly (Calc. 13938), 14067 = S-Glutathionylated (Calc. 14069), 14141 = CPPCHD-modified native form (Calc. 14142). For TTR, partial
peak splitting is due to incomplete monoisotopic resolution. Assigned “MH+“ values in deconvoluted spectra are centroided average masses.
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molecule will provide the most quantitatively accurate
estimate of the unstable species.
Assessment of 2-nitro-5-thiobenzoic acid as a
Quantitative Probe
2-nitro-5-thiobenzoic acid (a.k.a., thionitrobenzoic acid
or TNB) is the disulfide-reduced form of Ellman’s
reagent which is classically used for the determination
of free thiol groups in proteins. Recently, Turell et al
determined that the rate constant for TNB reaction with
albumin Cys-SOH is 105 M-1 s-1–over 3000 times
greater than that for unsubstituted dimedone and
5 times greater than that for free cysteine [24]. Thiols
do not spontaneously react with other thiols in the
absence of an oxidizing agent and, under the conditions
employed, TNB does not readily participate in intramo-
lecular disulfide exchange by reducing/inserting itself
into the existing disulfide bonds of albumin. When this
is the case, neither reduced thiols nor disulfides interfere
with TNB as a probe of Cys-SOH [24]. Under the
Table 1 Relative percent abundance (RPA) data for the mass spectra in Figures 1 and 4
Figure 1a – Albumin
m/z
66438
m/z
66470
m/z
66557
m/z 66600 & 66614 m/z 66655 m/z 66719 m/z 66818 Sample
Treatment
RPA
Native
RPA
SO2H
RPA
S-Cys
RPA Native Glycated &
S-CysGly
RPA NonCov. Phosphate
Adduct
RPA S-Cys + Glycation RPA CPPCHD
Adduct
H2O2 CPPCHD
32% 10% 38% 6% 3% 5% 6% + +
51% 0% 34% 9% 1% 5% 0% - +
32% 12% 43% 6% 3% 4% 0% + -
49% 0% 36% 6% 3% 5% 0% - -
Figure 1b – TTR
m/z
13761
m/z
13793
m/z
13880
m/z 13937 m/z 14067 m/z 14141 Sample
Treatment
RPA
Native
RPA
SO2H
RPA
S-Cys
RPA S-CysGly RPA S-Glutathione RPA CPPCHD Adduct H2O2 CPPCHD
23% 9% 48% 13% 3% 3% + +
39% 3% 46% 10% 3% 0% - +
21% 12% 52% 12% 3% 0% + -
39% 2% 48% 10% 1% 0% - -
Figure 4a – Albumin
m/z
66438
m/z
66470
m/z
66557
m/z 66600 & 66614 m/z 66636 m/z 66655 m/z 66719 Sample
Treatment
RPA
Native
RPA
SO2H
RPA
S-Cys
RPA Native Glycated &
S-CysGly
RPA TNB Adduct RPA NonCov. Phosphate
Adduct
RPA S-Cys +
Glycation
H2O2 TNB
32% 7% 37% 3% 15% 3% 4% + +
49% 0% 37% 5% 0% 4% 5% - +
32% 13% 42% 5% 0% 3% 4% + -
48% 0% 38% 7% 0% 3% 4% - -
Figure 4b – TTR
m/z
13761
m/z
13793
m/z
13880
m/z 13937 m/z 13959 m/z 14067 Sample
Treatment
RPA
Native
RPA
SO2H
RPA
S-Cys
RPA S-CysGly RPA TNB Adduct RPA S-Glutathione H2O2 TNB
19% 11% 48% 11% 7% 4% + +
29% IP 50% 9% 8% 4% - +
21% 12% 52% 12% 0% 3% + -
38% 2% 46% 12% 0% 2% - -
IP = “Interfering Peak”, cannot properly integrate
Rehder and Borges BMC Biochemistry 2010, 11:25
http://www.biomedcentral.com/1471-2091/11/25
Page 4 of 13
CHDCPP Probe
0
5
10
15
20
25
0 0.05 0.1 0.2 0.4 0.7 1 1.5 2 4 6 10
[H2O2] mM
R
el
at
iv
e 
P
er
ce
nt
 A
bu
nd
an
ce
 o
f C
HD
CP
P
-
M
od
ifi
ed
 P
ro
te
in
Dil-Albumin
MSIA-Albumin
MSIA-TTR
A
DCP-Bio1 Probe
0
5
10
15
20
25
0 0.05 0.1 0.2 0.4 0.7 1 1.5 2 4 6 10
[H2O2] mM
R
el
at
iv
e 
P
er
ce
nt
 A
bu
nd
an
ce
 o
f D
CP
-B
io
1-
M
od
ifi
ed
 P
ro
te
in
Dil-Albumin
MSIA-Albumin
MSIA-TTR
B
Figure 2 Relative percent abundance (RPA) of cysteine sulfenic acid on albumin (solid markers) as reported by the A) CPPCHD and B)
DCP-Bio1 Cys-SOH probes over a range of plasma concentrations of hydrogen peroxide. As shown for albumin, there is a significant
difference in the percent of modified protein detected when samples are prepared by dilution vs. MSIA. This demonstrates relative antibody
aversion for CPPCHD and DCP-Bio1-tagged forms of albumin. Additionally, the RPA values for cysteine sulfenic acid-modified albumin appear
significantly lower when trapped by (higher concentrations of) DCP-Bio1–demonstrating an empirical discrepancy in Cys-SOH trapping efficiency
between the two dimedone-based probes. Plasma from the same individual was used for collection of these datasets. Data on the RPA of
dimedone-tagged TTR (hollow markers) are shown for reference. RPA values decrease at the highest concentrations of hydrogen peroxide due
to overoxidation of Cys-SH to cysteine sulfinic acid (SO2H). Evidence to support this assertion can be seen as a +32 Da mass shift from the
Cys-SH form (and only the Cys-SH form) of the hydrogen peroxide treated samples in Figure 1, panel B.
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conditions used for the experiments described below, no
albumin modified by two or more molecules of TNB
was detected. This serves as experimental verification
that TNB was not reacting with protein disulfide bonds.
(Though not applicable to these studies, however, it is
possible for protein-TNB mixed disulfides to be
removed by intramolecular disulfide exchange wherein a
molecule of TNB is released and a disulfide bond is
formed between two cysteine residues that normally
interact with one another as part of normal protein
operation [50].)
To assess the utility of TNB as a quantitative probe
for the RPA of Cys-SOH-modified albumin and trans-
thyretin in human plasma, TNB was added to plasma at
increasing concentrations immediately after the plasma
was exposed to 4 mM hydrogen peroxide (for 2 min-
utes) then catalase. As described below, immediate pro-
tein purification and analysis (i.e., zero explicit TNB
incubation time) was found to be necessary to minimize
artifactual formation of Di-TNB (Ellman’s reagent/
DTNB) and subsequent labeling of free cysteine resi-
dues. As such, it was also important to minimize the
concentration of TNB added to plasma samples. At con-
centrations beyond 250 μM the addition of TNB did not
result in additional labeling of protein Cys-SOH
(Figure 3); thus this concentration of TNB was
employed in subsequent experiments.
Under these conditions TNB, like dimedone-based
probes, reacts specifically with Cys-SOH modified pro-
tein molecules (Figure 4). (RPA data of the different
protein forms can be seen in Table 1.) Interestingly,
based on its spontaneous reactivity with TNB in the
absence of exogenous hydrogen peroxide (Figure 4
Panel B, - H2O2/+ TNB trace), a significant proportion
of TTR protein molecules appear to possess native Cys-
SOH. This finding is not due to artifactual non-covalent
association of TNB with TTR. TNB only binds to the
native, free cysteine-containing form of TTR and not
the thiol-blocked S-cysteinylated form (Figure 4, Panels
C and D).
To assess analytical precision and the potential for
antibody bias against TNB-labeled protein, five replicate
plasma aliquots were incubated with hydrogen peroxide/
catalase and 250 μM TNB, then analyzed for TNB-mod-
ified albumin and TTR by both dilution and (as separate
samples) MSIA. For both albumin and TTR there was
no statistically significant difference in the RPA of TNB-
modified protein when samples were prepared by dilu-
tion vs. immunoaffinity extraction (Figure 5). Though,
for TTR, a t-test p-value of just over 0.06 suggests that
there may indeed be a slight antibody bias against TNB-
labeled protein molecules. For plasma prepared by dilu-
tion, the mean relative percent TNB-tagged albumin
was 19 ± 1.5 SE; by MSIA it was 18 ± 2.4 SE. For TTR,
these values were 7.2 ± 0.18 SE and 5.7 ± 1.2 SE,
respectively. These values have not previously been
reported for TTR because the existence of Cys-SOH
modified TTR was unknown. However, for albumin, our
results are consistent with a previously reported value
(18%) for percent Cys-SOH modification under similar
oxidative conditions but in the absence of a complex
biological matrix such as plasma [24]. Notably, these
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Figure 3 Relative percent abundance (RPA) of cysteine sulfenic acid on albumin (solid markers) and TTR (hollow markers) as reported
by increasing concentrations of TNB. Plasma samples were prepared by oxidation with 4 mM hydrogen peroxide for 2 minutes at 37°C,
followed by quenching with catalase, addition of TNB, immediate removal of TNB via gel filtration spin columns, 1000-fold dilution of plasma,
and analysis by ESI-MS.
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values may well vary depending on the percentage of
albumin molecules carrying a free cysteine residue. Dur-
ing the course of examining hundreds of individual
plasma samples, we have observed the percentage of
free cysteine-containing albumin to range from less than
5% to greater than 65% (Figure 6).
Analytical Precautions for the Use of TNB
When exposed to air for prolonged periods of time,
TNB can form disulfide homodimers–resulting in the
formation of DTNB which readily reacts with free
cysteine residues. As such, when employed as a trap
of Cys-SOH without precaution to prevent such
homodimer formation, erroneously high values for rela-
tive percent Cys-SOH abundance may be obtained.
To quantitatively determine the extent of this effect at
250 μM TNB, a fresh solution of TNB was prepared in
a 25 mM bicarbonate buffer containing 0.15 M NaCl
(pH 7.4) and monitored for loss of absorbance at 412
nm [24,51] over 15 minutes–a time period longer than
that required to immediately pass TNB-exposed plasma
through a gel filtration spin column (removing > 95% of
the TNB), dilute or immunoaffinity extract, and intro-
duce the resulting sample into a mass spectrometer.
(The molar absorptivity at 412 nm for DTNB is 211 M-1
cm-1 and that for TNB is 14,150 M-1 cm-1 [51].) Decay
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Figure 4 Mass spectra of A) albumin and B) TTR extracted from human plasma that was treated with/without hydrogen peroxide and
with/without the Cys-SOH trapping reagent TNB. For albumin (A), deconvoluted “MH+“ peaks are assigned as follows: 66439 = Native/
unmodified (Calc. 66439), 66558 = S-Cysteinylated (Calc. 66558), 66602 = Glycated native form (Calc. 66601), 66636 = TNB-adducted native form
(Calc. 66636), 66720 = Glycated S-Cysteinylated form (Calc. 66720). For TTR (B), 13762 = Native/unmodified (Calc. 13762), 13794 = Cys-sulfinic acid
(SO2H) due to over oxidation (Calc. 13794), 13881 = S-Cysteinylated (Calc. 13881), 13938 = S-CysGly (Calc. 13938), 13959 = TNB-adducted native
form (Calc. 13959). Assigned “MH+“ values in deconvoluted spectra are centroided average masses. All samples were immediately purified with a
gel filtration spin column upon addition of TNB and further prepared as quickly as possible for introduction into the mass spectrometer (~ 3
minutes for diluted samples and <15 minutes for MSIA samples). Albumin was prepared by dilution and TTR was prepared by MSIA (with the
exception of the - H2O2/
+ TNB sample for TTR which was prepared by dilution to facilitate the fastest possible introduction into the mass
spectrometer). Panels C and D provide extended views of the samples to which TNB was added, demonstrating that TNB reacts only with the
form of TTR which originally carried a free thiol. As illustrated, TNB does not bind noncovalently to S-cysteinylated or “thiol blocked” TTR.
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was limited to a loss of 0.5 μM/min, corresponding to a
potential maximum DTNB formation rate of 0.25 μM/
min. Conservative (i.e., overly abundant) incubations of
1-10 μM DTNB in plasma for 25 minutes showed that
this rate of formation of DTNB from TNB results in no
detectable (i.e., less than ~ 1% relative abundance)
formation of TNB-modified albumin and only trace/
marginally detectable quantities of TNB-modified TTR.
But given that, in our experiments, freshly reduced TNB
was employed (see Methods section) and >95% of TNB
was filtered out of our samples within seconds via cen-
trifugal gel filtration, it is reasonable to assert that
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Figure 5 Precision studies for the use of TNB (250 μM) as a trap of Cys-SOH in A) albumin and B) TTR, prepared from oxidized human
plasma by dilution and by MSIA. Each column represents the average ± standard error of 5 independent samples. No statistically significant
differences were noted for dilution vs. MSIA.
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artifactual formation of DTNB and its subsequent con-
tribution to our measured RPA values of TNB-modified
protein was negligible.
Advantages and Disadvantages of Cys-SOH Relative
Quantification by Mass Spectrometric Analysis of Intact
Proteins
When coupled with a rapid purification technique, mass
spectral analysis of intact proteins provides a degree of
molecular detail and an ability to analyze proteins in
complex biological matrices that is essentially impossible
to match with other available techniques such as spec-
trophotometry or western blotting. For example, the
mass spectral data shown in Figures 4c and 4d readily
reveal that only the protein molecules with an available
free cysteine residue are modified by TNB (whether or
not H2O2 was used as an oxidant). Protein molecules in
which the single free cysteine residue was already
S-cysteinylated remained unmodified.
A potential criticism of the technique is that possible
differences in ionization efficiency between differentially
modified protein molecules may render relative quantifi-
cation of the different protein forms inaccurate–i.e., that
resulting mass spectral integrals may not represent the
exact molar percentage of each protein variant detected.
However, considering the overall size of proteins and
the sheer number of charges on each protein molecule
(+8 to +19 for TTR and +30 to +66 for albumin)
coupled with the at-most ± 1 charge-unit effect of a sin-
gle differential substituent on whole protein ionization,
the argument for an effect of ionization efficiency on
apparent molar abundances becomes negligible.
Physiological Relevance
With few exceptions, most studies of protein-SOH
described in the literature involve induction of protein-
SOH using non-physiological concentrations of exogen-
ous oxidants such as H2O2. Because the addition of exo-
genous oxidants to create protein-SOH is required for
most proteins, the RPAs of protein-SOH observed in
this and other studies reported in the literature are cer-
tainly higher than might be found physiologically. How-
ever, this study, as well as others, clearly shows that
mixed protein-glutathione and protein-cysteine disul-
fides exist naturally in significant quantities. Based on
the observations reported in this study, we hypothesize
that a major physiological role of protein-SOH (for the
vast majority of proteins) is to serve as an oxidative
intermediate in the formation of reversible mixed pro-
tein disulfides. As such, the in vivo RPA of protein-SOH
in most proteins at any given instant in time will likely
be low.
Conclusions
Molecular probes which covalently trap Cys-SOH can
yield modified proteins that are less well-recognized by
antibodies than their unmodified/natural counterparts.
Each combination of protein, probe, and antibody stands
to differ in this effect and must be investigated empiri-
cally. Dimedone-based probes of Cys-SOH are useful for
detecting the presence of protein-specific Cys-SOH
within complex biological matrices [5,25-28], but with
regard to relative quantification, their reaction rates
with Cys-SOH may be outpaced by reactions with endo-
genous thiols. TNB reacts faster with Cys-SOH than
endogenous thiols or dimedone [24]; we have shown
herein that when proper precautions are taken to ensure
its stability, TNB’s fast reaction rate, limited antibody
66100 66200 66300 66400 66500 66600 66700 66800 66900 m/z
66100 66200 66300 66400 66500 66600 66700 66800 66900 m/z
66440
Native, free cysteine-
containing albumin
66440
66559
66602
66538
66325
66254
66559
66721
S-Cysteinylated albumin
A
B
Figure 6 Illustration of the wide range of relative percent
abundances of Native and S-Cysteinylated albumin found in
the human population. Data were acquired from human plasma
obtained from A) an individual with congestive heart failure,
diabetes, and a history of myocardial infarction (4.5% Native form),
and B) a healthy individual (66% Native form). Deconvoluted “MH+“
peaks are assigned as follows: 66254 = N-terminal truncation (-DA)
(Calc. 66253), 66325 = N-terminal truncation (-D) (Calc. 66324),
66440 = Native/unmodified (Calc. 66439), 66538 = Non-covalent
phosphate adduct (plasma anticoagulant artifact) (Calc. 66537),
66559 = S-Cysteinylated (Calc. 66558), 66602 = Glycated native form
(Calc. 66601), 66721 = Glycated S-Cysteinylated form (Calc. 66720).
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bias, and net mass shift make it useful in the relative
quantification of Cys-SOH on specific proteins within
human plasma when mass spectrometry is employed for
detection. Transthyretin in its native environment
appears to be modified by Cys-SOH in the absence of
exogenous oxidants. Amongst different individuals, free
cysteine-containing plasma proteins can vary widely in
the fraction of protein molecules carrying free thiol
groups. Thus ultimately, to understand and properly
interpret the relative quantification of protein modifica-
tion by Cys-SOH, it is necessary to be aware of this per-
centage of target protein molecules that contain free
thiol groups and thus are available for modification by
Cys-SOH.
Methods
Materials
Human plasma from a single healthy female donor and
a single healthy male donor was purchased from Pro-
MedDx. Plasma samples were collected offsite under
IRB approval and, prior to purchase, were publicly avail-
able. Plasma samples were received with all personal
identifiers removed, allowing the authors to operate
under human subjects “Exemption 4” classification pur-
suant to Federal regulations 45 CFR Part 46.101(b)(4)
(Arizona State University IRB Protocol #: 0705001851,
approved 18 May, 2007). Plasma was stored at -80°C
until analysis. MSIA pipette tips containing frits with a
carboxydextran surface were obtained from Intrinsic
Bioprobes, Inc. (Tempe, AZ). Affinity purified polyclonal
anti-human serum albumin (Cat. No. A0001) and anti-
human transthyretin (Cat. No. A0002) were obtained
from DAKO (Carpinteria, CA). 5-[2-(3-chlorophenoxy)
phenyl]-4-(1H-1,2,4-triazol-1-yl)-1,3-cyclohexanedione
(CPPCHD) was purchased from Ryan Scientific. DCP-
Bio1 was generously supplied by Dr. Bruce King of
Wake Forest University. Premixed 0.6 M sodium citrate/
0.1 M sodium carbonate (pH 9) buffer packets (Cat. No.
28388), 0.5 mL Zeba™ desalting gel filtration spin col-
umns (MWCO = 7,000 Da; Cat. No. 89883) and immo-
bilized tris(carboxyethyl) phosphine disulfide reducing
gel (Cat. No. 77712) were acquired from Pierce. HEPES
buffered saline (10 mM HEPES, 0.15 M NaCl, pH 7.4;
a.k.a. HBS-N) was purchased from GE Healthcare Life
Sciences. Five-milliliter HiTrap Q® ion exchange car-
tridges (Cat No. 54816) and all other chemicals and
reagents were from Sigma-Aldrich.
TNB Synthesis, Purification, Storage and Use
Thionitrobenzoate (TNB) was synthesized by reduction
of 5,5′-Dithiobis(2-nitrobenzoic acid) (a.k.a. Ellman’s
reagent/DTNB) and purified as described elsewhere
[24]. Briefly, 40 mL of a 5 mM solution of DTNB was
made by alkalinizing a DTNB suspension with NaOH
until it completely dissolved. The final pH was 8.5 - 9.
A 40-fold excess of b-mercaptoethanol (630 μL) was
mixed with the DTNB and allowed to react for 45 min-
utes at room temperature. Resulting TNB was purified
over a 5-mL HiTrap Q® ion exchange cartridge as fol-
lows: The cartridge was prerinsed with 25 mL water,
then 25 mL of 50 mM HCl, another 25 mL water, then
30 mL of 20 mM Tris, pH 7.5. After applying the TNB
sample, the cartridge was rinsed with 25 mL of 20 mM
Tris, pH 7.5, 30 mL water, then eluted with 50 mM
HCl. The most intensely yellow-colored 1.5-mL fractions
were pooled together. TNB concentration was measured
by diluting an aliquot of product 200-fold in 0.6 M
citrate/0.1 M carbonate buffer, pH 9 and measuring
optical absorbance at 412 nm (at which ε = 14,150 M-1
cm-1 above pH 7.3 [51]). One-half milliliter aliquots
were stored frozen at -80°C until use, at which time
they were thawed at room temperature over 50 μL of
immobilized TCEP. Immediately after thawing, 60 μL of
0.5 M NaOH containing 5 mM DTPA was added and
mixed well. During use, aliquots were kept on ice but
vortexed and quickly sedimented by brief centrifugation
prior to each withdrawal of an aliquot. This procedure
was found to keep the concentration of TNB constant
for at least 6 hours.
Immobilization of Antibodies on MSIA Pipette Tips
To prepare MSIA pipette tips for antibody immobiliza-
tion, the unmodified carboxydextran surfaces were rinsed
thoroughly with 0.2 M HCl then acetone using a Beck-
man Multimek 96 pipetting robot. Tips were subse-
quently ejected and dried under vacuum. After drying,
the tips were activated by exposure to 150 μL of 1,1′-car-
bonyldiimidazole (50 g/L) in 1-methyl-2-pyrrolidinone
for 30 minutes. This was accomplished by repeatedly
pipetting (aspirating and dispensing) 100 μL of solution
over the tip frits. After two brief rinses in 1-methyl-2-
pyrrolidinone, tips were exposed to a 0.05 g/L solution of
anti-human albumin or anti-human TTR in 0.1 M MES
buffered saline, pH 4.7 by repetitively flowing (aspirating
and dispensing 750 times) 50 μL volumes of antibody
solution (150 μL/well) through the pipette tips. Tips were
subsequently blocked with 1 M ethanolamine, pH 8.5
(400 μL/well; 50 × 150 μL aspirate and dispense steps)
then exposed to 60 mM HCl 2*(400 μL/well; 50 × 150 μL
aspirate and dispense steps) and equilibrated in HEPES
buffered saline (HBS-N) 2*(400 μL/well; 50 × 150 μL
aspirate and dispense steps). Anti-human serum albumin
and anti-human TTR-linked pipette tips were stored in
HBS-N at 4°C until the day of use.
Trapping Cys-SOH in Plasma Proteins
In most but not all cases, hydrogen peroxide was added
to plasma samples to induce formation of protein
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Cys-SOH. Thus, to 50 μL of plasma was added 1 μL of
an appropriate stock concentration of hydrogen perox-
ide to produce the desired final concentration of H2O2
(usually 4 mM). In some experiments, reaction volumes
were doubled (but concentrations held constant). Stock
concentrations of hydrogen peroxide were checked for
stability by measuring optical absorbance at 240 nm
(at which ε = 43.6 M-1 cm-1 [24]). Unless otherwise
indicated, plasma samples were incubated at 37°C for
2 minutes, at which time enough volume of a 2 g/L
solution of catalase was added to consume 90% of the
hydrogen peroxide in 1 second [24]. Cys-SOH probes
were added immediately thereafter. For CPPCHD, 3.8
μL of a 130 mM solution in DMSO was added and
incubated at 37°C for 30 minutes. For DCP-Bio1, 3.8 μL
of a 250 mM solution in DMSO was added and incu-
bated at 37°C for 30 minutes. Samples were then either
diluted 2-fold with HBS-N in preparation for extraction
by MSIA or diluted 1000-fold in starting LC/MS mobile
phase for direct analysis.
When Cys-SOH was trapped with TNB ~ 1 μL of a
12 mM stock solution of TNB was added to produce
the final desired concentration of TNB (usually
250 μM). Because of problems with instability (see
Results and Discussion), TNB was allowed no explicit
reaction time with plasma proteins, but samples were
instead immediately applied to a Zeba™ desalting gel fil-
tration spin column (MWCO = 7,000 Da) following the
manufacturer recommendations for removal of small
molecules. The high rate constant for reaction of TNB
with accessible protein Cys-SOH [24] ensured that TNB
was given adequate time to react with protein Cys-SOH,
even during this short duration of time. After elimina-
tion of small molecules from these plasma samples, they
were immediately extracted by MSIA or diluted 1000-
fold (in 90/10 water/acetonitrile containing 0.1% formic
acid) in preparation for LC-ESI-MS. In the latter case,
only ~3 minutes were allowed to elapse after introduc-
tion of TNB into the sample prior to introduction of
the sample into the LC-MS; in the former case of
MSIA, <15 minutes was allowed to elapse.
Plasma Protein Analysis by MSIA
Following a preliminary rinse with fresh HBS-N, anti-
human albumin or anti-human TTR-derivatized MSIA
pipette tips were used to extract albumin and TTR from
plasma samples. This was done by aspirating and dis-
pensing the plasma over the MSIA frit with the aid of
an electronic pipettor for 10 minutes. MSIA tips were
then washed (by drawing from a fresh reservoir of liquid
and dispensing to waste) and eluted as follows: Five
cycles of 200 μL of HBS-N, five cycles of 200 μL dis-
tilled water, five cycles of 200 uL of 2 M ammonium
acetate/acetonitrile (3:1 v/v), ten cycles of 200 uL of
distilled water. Elution was accomplished by briefly air-
drying the pipette frits then drawing 5 μL of a mixture
of 100% formic acid/acetonitrile/distilled water (9/5/1
v/v/v), mixing over the pipette affinity capture frit for
30 seconds, and dispensing into a 96-conical well poly-
propylene autosampler tray. Frits were then washed with
an additional 5.5 μL distilled water which was used to
dilute the eluted sample. Five microliters of eluent was
then immediately injected onto the LC-ESI-MS.
Unlike absolute quantitative analysis in which percent
recovery can be an important analytical parameter, ana-
lysis of RPA as carried out here depends primarily on
achieving good ion counting statistics in the mass spec-
trometer. The picomole quantities of protein captured
by the MSIA tips are more than sufficient to provide
excellent ion counting statistics and signal to noise
ratios in the mass spectrometer.
Prior to collecting the data presented in this report,
reproducibility of the albumin assay was verified by ana-
lyzing albumin in 20 different samples from individual
donors run in quadruplicate each. Average CV for the
RPA of the native form of albumin was 3.8% and that
for glycated albumin was 6.5%. Reproducibility data for
the analysis of TTR by MSIA have previously been
described [37].
LC-ESI-TOF Mass Spectrometric Analysis of Albumin and
Transthyretin
The analysis of human serum albumin and TTR by
reversed phase liquid chromatography electrospray ioni-
zation mass spectrometry (LC-ESI-MS) was performed
by a trap-and-elute form of LC (rather than traditional
LC) on an Eksigent nanoLC*1D LC system. Five-microli-
ter samples were injected by a Spark Holland Endurance
autosampler in microliter pick-up mode and loaded onto
a protein captrap (polymeric/reversed phase sorbent,
Michrom Bioresources, Auburn, CA) configured for uni-
directional flow on a 6-port divert valve. Mobile phase A
consisted of 90% H2O/10% acetonitrile, 0.1% formic acid
and was used as a high-flow loading solvent at 10 μL per
minute. After 2 minutes, the divert valve position was
automatically toggled and flow rate over the protein cap-
trap cartridge changed to 1 μL/min. Flow was then
ramped over 8 minutes using a linear gradient from 10%
to 90% mobile phase B (100% acetonitrile). The captrap
eluate was directed to a Bruker MicrOTOF-Q (Q-TOF)
mass spectrometer operating in positive ion, TOF-only
mode, acquiring spectra in the m/z range of 300 to 3000.
ESI settings for the Agilent G1385A capillary microflow
nebulizer ion source were as follows: End Plate Offset
-500 V, Capillary -4500 V, Nebulizer nitrogen 2 Bar, Dry
Gas nitrogen 3.0 L/min at 225°C. Data were acquired in
profile mode at a digitizer sampling rate of 2 GHz. Spec-
tra rate control was by summation at 1 Hz.
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Data Analysis for Intact Human Serum Albumin and
Transthyretin
Approximately 1-1.5 minutes of recorded spectra were
averaged across the chromatographic peak apex of
human serum albumin and transthyretin elution. The
ESI charge-state envelope was deconvoluted with Bruker
DataAnalysis v3.4 software to a mass range of 1000 Da
on either side of any identified peak. Deconvoluted spec-
tra were baseline subtracted and all peaks were inte-
grated. Tabulated mass spectral peak areas were
exported to a spreadsheet for further calculation and
determination of the peak areas of interest relative to all
other variant forms of albumin or TTR present in the
mass spectrum.
List of Abbreviations
Cys-SOH: Cysteine sulfenic acid; RPA: relative percent abundance; MSIA: mass
spectrometric immunoassay; TTR: transthyretin; CPPCHD: 5-[2-(3-
chlorophenoxy)phenyl]-4-(1H-1,2,4-triazol-1-yl)-1,3-cyclohexanedione; TNB:
thionitrobenzoic acid; DTNB: 5,5′-Dithiobis(2-nitrobenzoic acid); HBS-N: HEPES
buffered saline
Authors’ contributions
DSR participated in experimental design, acquired most of the data, and
helped draft the manuscript. CRB participated in experimental design,
acquired some of the data and wrote most of the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
The authors are grateful to Dr. Leslie Poole and Dr. Bruce King of Wake
Forest University for providing useful feedback on this manuscript and for
supplying DCP-Bio1. As it relates to DCP-Bio1, this work was supported in
part by NIH grant R33 CA126659 to Dr. Leslie B. Poole. The remainder of this
research was supported by the National Institutes of Health Grant
R21RR024440 to CRB.
Received: 11 February 2010 Accepted: 1 July 2010
Published: 1 July 2010
References
1. Poole LB, Karplus PA, Claiborne A: Protein sulfenic acids in redox
signaling. Annu Rev Pharmacol Toxicol 2004, 44:325-347.
2. Reynaert NL, van der Vliet A, Guala AS, McGovern T, Hristova M, Pantano C,
Heintz NH, Heim J, Ho YS, Matthews DE, et al: Dynamic redox control of
NF-kappaB through glutaredoxin-regulated S-glutathionylation of
inhibitory kappaB kinase beta. Proc Natl Acad Sci USA 2006,
103(35):13086-13091.
3. Poole LB, Nelson KJ: Discovering mechanisms of signaling-mediated
cysteine oxidation. Current opinion in chemical biology 2008, 12(1):18-24.
4. Helmann JD: OxyR: a molecular code for redox sensing? Sci STKE 2002,
2002(157):PE46.
5. Michalek RD, Nelson KJ, Holbrook BC, Yi JS, Stridiron D, Daniel LW,
Fetrow JS, King SB, Poole LB, Grayson JM: The requirement of reversible
cysteine sulfenic acid formation for T cell activation and function.
J Immunol 2007, 179(10):6456-6467.
6. Allison WS: Formation and reactions of sulfenic acids in proteins. Accts of
Chem Res 1976, 9:293-299.
7. Allison WS, Connors MJ: The activation and inactivation of the acyl
phosphatase activity of glyceraldehyde-3-phosphate dehydrogenase.
Arch Biochem Biophys 1970, 136(2):383-391.
8. You KS, Benitez LV, McConachie WA, Allison WS: The conversion of
glyceraldehyde-3-phosphate dehydrogenase to an acylphosphatase by
trinitroglycerin and inactivation of this activity by azide and ascorbate.
Biochim Biophys Acta 1975, 384(2):317-330.
9. Lin WS, Armstrong DA, Gaucher GM: Formation and repair of papain
sulfenic acid. Canadian journal of biochemistry 1975, 53(3):298-307.
10. Claiborne A, Miller H, Parsonage D, Ross RP: Protein-sulfenic acid
stabilization and function in enzyme catalysis and gene regulation. Faseb
J 1993, 7(15):1483-1490.
11. Claiborne A, Yeh JI, Mallett TC, Luba J, Crane EJ, Charrier V,
Parsonage D: Protein-sulfenic acids: diverse roles for an unlikely
player in enzyme catalysis and redox regulation. Biochemistry 1999,
38(47):15407-15416.
12. Georgiou G: How to flip the (redox) switch. Cell 2002, 111(5):607-610.
13. Fuangthong M, Helmann JD: The OhrR repressor senses organic
hydroperoxides by reversible formation of a cysteine-sulfenic acid
derivative. Proc Natl Acad Sci USA 2002, 99(10):6690-6695.
14. Carballal S, Radi R, Kirk MC, Barnes S, Freeman BA, Alvarez B: Sulfenic acid
formation in human serum albumin by hydrogen peroxide and
peroxynitrite. Biochemistry 2003, 42(33):9906-9914.
15. Carballal S, Alvarez B, Turell L, Botti H, Freeman BA, Radi R: Sulfenic acid in
human serum albumin. Amino Acids 2007, 32(4):543-551.
16. Yeh JI, Claiborne A, Hol WG: Structure of the native cysteine-sulfenic acid
redox center of enterococcal NADH peroxidase refined at 2.8 A
resolution. Biochemistry 1996, 35(31):9951-9957.
17. Choi HJ, Kang SW, Yang CH, Rhee SG, Ryu SE: Crystal structure of a novel
human peroxidase enzyme at 2.0 A resolution. Nat Struct Biol 1998,
5(5):400-406.
18. Wood ZA, Schroder E, Robin Harris J, Poole LB: Structure, mechanism and
regulation of peroxiredoxins. Trends Biochem Sci 2003, 28(1):32-40.
19. Seth D, Rudolph J: Redox regulation of MAP kinase phosphatase 3.
Biochemistry 2006, 45(28):8476-8487.
20. Becker K, Savvides SN, Keese M, Schirmer RH, Karplus PA: Enzyme
inactivation through sulfhydryl oxidation by physiologic NO-carriers. Nat
Struct Biol 1998, 5(4):267-271.
21. Benitez LV, Allison WS: The inactivation of the acyl phosphatase activity
catalyzed by the sulfenic acid form of glyceraldehyde 3-phosphate
dehydrogenase by dimedone and olefins. J Biol Chem 1974,
249(19):6234-6243.
22. Reddie KG, Carroll KS: Expanding the functional diversity of proteins
through cysteine oxidation. Current opinion in chemical biology 2008,
12(6):746-754.
23. Poole LB, Klomsiri C, Knaggs SA, Furdui CM, Nelson KJ, Thomas MJ,
Fetrow JS, Daniel LW, King SB: Fluorescent and affinity-based tools to
detect cysteine sulfenic acid formation in proteins. Bioconjug Chem 2007,
18(6):2004-2017.
24. Turell L, Botti H, Carballal S, Ferrer-Sueta G, Souza JM, Duran R, Freeman BA,
Radi R, Alvarez B: Reactivity of sulfenic acid in human serum albumin.
Biochemistry 2008, 47(1):358-367.
25. Saurin AT, Neubert H, Brennan JP, Eaton P: Widespread sulfenic acid
formation in tissues in response to hydrogen peroxide. Proc Natl Acad Sci
USA 2004, 101(52):17982-17987.
26. Charles RL, Schroder E, May G, Free P, Gaffney PR, Wait R, Begum S,
Heads RJ, Eaton P: Protein sulfenation as a redox sensor: proteomics
studies using a novel biotinylated dimedone analogue. Mol Cell
Proteomics 2007, 6(9):1473-1484.
27. Reddie KG, Seo YH, Muse Iii WB, Leonard SE, Carroll KS: A chemical
approach for detecting sulfenic acid-modified proteins in living cells.
Molecular bioSystems 2008, 4(6):521-531.
28. Seo YH, Carroll KS: Profiling protein thiol oxidation in tumor cells using
sulfenic acid-specific antibodies. Proc Natl Acad Sci USA 2009,
106(38):16163-16168.
29. Nelson RW, Krone JR, Bieber AL, Williams P: Mass spectrometric
immunoassay. Anal Chem 1995, 67(7):1153-1158.
30. Kiernan UA, Nedelkov D, Niederkofler EE, Tubbs KA, Nelson RW: High-
throughput affinity mass spectrometry. Methods Mol Biol 2006,
328:141-150.
31. Kiernan UA, Tubbs KA, Gruber K, Nedelkov D, Niederkofler EE, Williams P,
Nelson RW: High-throughput protein characterization using mass
spectrometric immunoassay. Anal Biochem 2002, 301(1):49-56.
32. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW:
Investigating diversity in human plasma proteins. Proc Natl Acad Sci USA
2005, 102(31):10852-10857.
Rehder and Borges BMC Biochemistry 2010, 11:25
http://www.biomedcentral.com/1471-2091/11/25
Page 12 of 13
33. Nedelkov D, Phillips DA, Tubbs KA, Nelson RW: Investigation of human
protein variants and their frequency in the general population. Mol Cell
Proteomics 2007, 6(7):1183-1187.
34. Nedelkov D, Tubbs KA, Niederkofler EE, Kiernan UA, Nelson RW: High-
throughput comprehensive analysis of human plasma proteins: a step
toward population proteomics. Anal Chem 2004, 76(6):1733-1737.
35. Borges CR, Jarvis JW, Oran PE, Nelson RW: Population studies of vitamin d
binding protein microheterogeneity by mass spectrometry lead to
characterization of its genotype-dependent o-glycosylation patterns.
J Proteome Res 2008, 7(9):4143-4153.
36. Kiernan UA, Addobbati R, Nedelkov D, Nelson RW: Quantitative
multiplexed C-reactive protein mass spectrometric immunoassay.
J Proteome Res 2006, 5(7):1682-1687.
37. Kiernan UA, Nedelkov D, Nelson RW: Multiplexed mass spectrometric
immunoassay in biomarker research: a novel approach to the
determination of a myocardial infarct. J Proteome Res 2006,
5(11):2928-2934.
38. Nedelkov D: Mass spectrometry-based immunoassays for the next phase
of clinical applications. Expert review of proteomics 2006, 3(6):631-640.
39. Nelson RW, Nedelkov D, Tubbs KA, Kiernan UA: Quantitative mass
spectrometric immunoassay of insulin like growth factor 1. J Proteome
Res 2004, 3(4):851-855.
40. Niederkofler EE, Kiernan UA, O’Rear J, Menon S, Saghir S, Protter AA,
Nelson RW, Schellenberger U: Detection of Endogenous B-Type
Natriuretic Peptide at Very Low Concentrations in Patients with Heart
Failure. Circulation: Heart Failure 2008, 1:258-264.
41. Niederkofler EE, Tubbs KA, Gruber K, Nedelkov D, Kiernan UA, Williams P,
Nelson RW: Determination of beta-2 microglobulin levels in plasma
using a high-throughput mass spectrometric immunoassay system. Anal
Chem 2001, 73(14):3294-3299.
42. Tubbs KA, Kiernan UA, Niederkofler EE, Nedelkov D, Bieber AL, Nelson RW:
Development of recombinant-based mass spectrometric immunoassay
with application to resistin expression profiling. Anal Chem 2006,
78(10):3271-3276.
43. Turell L, Botti H, Carballal S, Radi R, Alvarez B: Sulfenic acid–a key
intermediate in albumin thiol oxidation. J Chromatogr B Analyt Technol
Biomed Life Sci 2009, 877(28):3384-3392.
44. Turell L, Carballal S, Botti H, Radi R, Alvarez B: Oxidation of the albumin
thiol to sulfenic acid and its implications in the intravascular
compartment. Brazilian journal of medical and biological research = Revista
brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica
[et al] 2009, 42(4):305-311.
45. Tetko IV, Tanchuk VY, Kasheva TN, Villa AE: Estimation of aqueous
solubility of chemical compounds using E-state indices. Journal of
chemical information and computer sciences 2001, 41(6):1488-1493.
46. Poole LB: Personal Communication. 2009.
47. Nakanishi T, Hasuike Y, Otaki Y, Hama Y, Nanami M, Miyagawa K,
Moriguchi R, Nishikage H, Izumi M, Takamitsu Y: Free cysteine is increased
in plasma from hemodialysis patients. Kidney international 2003,
63(3):1137-1140.
48. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, Ji J,
Otto JM, Taylor LM Jr: Rapid HPLC determination of total homocysteine
and other thiols in serum and plasma: sex differences and correlation
with cobalamin and folate concentrations in healthy subjects. Clin Chem
1994, 40(6):873-881.
49. Chwatko G, Bald E: Determination of cysteine in human plasma by high-
performance liquid chromatography and ultraviolet detection after pre-
column derivatization with 2-chloro-1-methylpyridinium iodide. Talanta
2000, 52(3):509-515.
50. Jonsson TJ, Ellis HR, Poole LB: Cysteine reactivity and thiol-disulfide
interchange pathways in AhpF and AhpC of the bacterial alkyl
hydroperoxide reductase system. Biochemistry 2007, 46(19):5709-5721.
51. Reiner CK, Kada G, Gruber HJ: Quick measurement of protein sulfhyrdyls
with Ellman’s reagent and with 4,4′-dithiodipyridine. Anal Bioanal Chem
2002, 373:266-276.
doi:10.1186/1471-2091-11-25
Cite this article as: Rehder and Borges: Possibilities and pitfalls in
quantifying the extent of cysteine sulfenic acid modification of specific
proteins within complex biofluids. BMC Biochemistry 2010 11:25.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rehder and Borges BMC Biochemistry 2010, 11:25
http://www.biomedcentral.com/1471-2091/11/25
Page 13 of 13
